Inhaled nitric oxide versus inhaled prostacyclin and intravenous versus inhaled prostacyclin in acute respiratory failure with pulmonary hypertension in piglets

• Published in: Pediatric research Vol. 38; no. 2; pp. 198 - 204
• Main Authors: ZOBEL, G, DACAR, D, RÖDL, S, FRIEHS, I
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 01.08.1995
• Subjects: Acute Disease; Administration, Inhalation; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Animals; Biological and medical sciences; Disease Models, Animal; Emergency and intensive care: neonates and children. Prematurity. Sudden death; Epoprostenol - therapeutic use; Evaluation Studies as Topic; Female; Hemodynamics - drug effects; Hypertension, Pulmonary - drug therapy; Hypertension, Pulmonary - etiology; Hypertension, Pulmonary - physiopathology; Intensive care medicine; Male; Medical sciences; Nitric Oxide - therapeutic use; Random Allocation; Respiratory Insufficiency - complications; Respiratory Insufficiency - drug therapy; Respiratory Insufficiency - physiopathology; Swine; Intravenous administration; Prostaglandin I2; Prostaglandin; Respiratory disease; Treatment efficiency; Cardiovascular disease; Young animal; Pulmonary hypertension; Inhalation; Pig; Gases; Vertebrata; Chemotherapy; Mammalia; Treatment; Respiratory failure; Nitrogen monoxide; Arterial pressure; Blood pressure; Artiodactyla; Hemodynamics; Oxygenation; Ungulata; Comparative study
• ISSN: 0031-3998; 1530-0447
• DOI: 10.1203/00006450-199508000-00011

This study was a prospective, randomized design to compare oxygenation and pulmonary hemodynamics between inhaled nitric oxide (NO) and inhaled prostacyclin (PGI2), and between inhaled and i.v. PGI2 in acute respiratory failure with pulmonary hypertension. Acute respiratory failure with pulmonary hypertension was induced in 12 piglets weighing 9-12 kg by repeated lung lavages and a continuous infusion of the stable endoperoxane analogue of thromboxane. Thereafter the animals were randomly assigned either for NO or PGI2 application. All animals were treated with different concentrations of NO or different doses of PGI2 applied i.v. and inhaled in random order. Continuous monitoring included ECG, central venous pressure (CVP), mean pulmonary artery pressure (MPAP), mean arterial pressure (MAP), arterial oxygen saturation (SaO2), and mixed venous oxygen saturation (SvO2) measurements. NO inhalation of 10 ppm resulted in a significant increase in PaO2/fraction of inspired oxygen (FiO2) from 7.8 +/- 1.34 kPa to 46.1 +/- 9.7 kPa. MPAP decreased significantly from 5.1 +/- 0.26 kPa to 3.7 +/- 0.26 kPa during inhaled NO of 40 ppm; i.v. infusion of PGI2 slightly increased oxygenation parameters. A significant increase in PaO2/FiO2 up to 32.4 +/- 3.1 kPa was observed during PGI2 aerosol delivery (p < 0.01); i.v. PGI2 decreased MAP from 11.5 +/- 0.39 kPa to 9.8 +/- 0.66 kPa (p < 0.05) and MPAP from 5.8 +/- 0.53 kPa to 4.5 +/- 0.66 kPa, respectively (p < 0.05). PGI2 aerosol delivery significantly decreased the MPAP to 3.7 +/- 0.53 kPa (p < 0.05) without influencing the MAP.